Residual Disease heterogeneity After Neoadjuvant Systemic Therapy in Breast Cancer
Wide prognostic and biologic heterogeneity exists within the definition of residual disease after neoadjuvant systemic therapy for breast cancer.
This article reviews strategies to dissect such heterogeneity and leverage it to improve patients’ outcomes.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2823546
https://sciencemission.ayurmatrika.com/Heterogeneity-of-Residual-Disease-After-Neoadjuvant-Systemic-Therapy-in-Breast-Cancer
